Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab

• Published in: Biochimica et biophysica acta. Proteins and proteomics 2021-02, Vol.1869 (2), p.140563, Article 140563
• Main Authors: Landi, Claudia, Cameli, Paolo, Vantaggiato, Lorenza, Bergantini, Laura, d'Alessandro, Miriana, Perruzza, Marco, Carleo, Alfonso, Shaba, Enxhi, Di Giuseppe, Fabrizio, Angelucci, Stefania, Bargagli, Elena, Bini, Luca
• Format: Article
• Language: English
• Subjects: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Asthma - blood; Asthma - drug therapy; Asthma - genetics; Asthma - pathology; Benralizumab; Ceruloplasmin - metabolism; Eosinophils - metabolism; Eosinophils - pathology; Female; Gene Expression Regulation - drug effects; Humans; Inflammation - blood; Inflammation - drug therapy; Inflammation - genetics; Inflammation - pathology; Interleukin-5 - blood; Male; Mepolizumab; Middle Aged; Oxidation-Reduction; Oxidative Stress - drug effects; Proteomics - methods; Receptors, Interleukin-5 - blood; Redox proteomics; Serum; Severe eosinophilic asthma
• ISSN: 1570-9639; 1878-1454
• DOI: 10.1016/j.bbapap.2020.140563

Severe eosinophilic asthma has been associated with Th2 airway inflammation and elevated proinflammatory cytokines and chemokines, such as IL-5. Precision therapies have recently been shown to improve asthma symptoms with a steroid-sparing effect. Two such therapies, Benralizumab and Mepolizumab, humanized IgG antibodies directed against the IL-5 receptor and IL-5, have been approved for severe eosinophilic asthma. Here we used a differential proteomic approach to analyse serum from patients with severe eosinophilic asthma treated with Benralizumab and Mepolizumab in a search for differential molecular modifications responsible of their effects. Enrichment analysis of differential proteins was performed for the two treatments. After one month of Benralizumab treatment we detected up-regulation of certain protein species of the antioxidant ceruloplasmin. To investigate oxidative stress, we performed redox proteomics which detected lower oxidative burst after one month of Benralizumab treatment than in the pre-treatment phase or after one month of Mepolizumab therapy. •Serum proteomic comparison of severe asthma patients treated with Mepolizumab and Benralizumab•Response to therapy biomarkers identification•Ceruloplasmin, an antioxidant protein, was proved to be up-regulated after Benralizumab treatment.•Redox proteomics confirmed lower oxidative burst after one month of Benralizumab than after Mepolizumab.